Non-small cell lung cancer with MET mutation: a clinical case of treatment with MET inhibitor capmatinib

The MET gene encodes cell surface receptors that have tyrosine kinase activity and mediates embryonic development, organogenesis, and wound healing. Overexpression of MET is observed in some human cancers, including non-small cell lung cancer. Capmatinib is a selective type Ib inhibitor of MET. A total of 151 patients with MET exon 14 skipping mutations were enrolled in the GEOMETRY-mono 1 study. ORR achieved was 51% in patients receiving second-line chemotherapy, the median PFS was 6.9 months. We present a clinical case of NSCLC treatment in a pretreated patient aged 50 years with MET exon 14 skipping mutations. The MET mutation was detected by next-generation sequencing. Initially, the patient presented with metastatic disease, underwent surgical treatment due to lung cancer complications. She received a platinum-containing chemotherapy regimen as the first-line therapy, and in case of progression, targeted therapy was considered. Currently, progression-free survival is 9 months. This clinical observation shows the efficacy of targeted capmatinib therapy in a pretreated patient with advanced NSCLC and MET exon 14 skipping mutations. Testing of patients with advanced non-squamous non-small cell lung cancer for rare mutations such as MET, RET is clearly needed.